Naturally occurring compounds acting as potent anti-metastatic agents and their suppressing effects on Hedgehog and WNT/β-catenin signalling pathways

Cell Proliferation

Volumn 50, Issue 1, 2017, Pages

  Farahmand, L ^a   Darvishi, B ^a   Majidzadeh A, K ^a,b   Madjid Ansari, A ^a  

^a AVICENNA RESEARCH INSTITUTE   (Iran)

^b AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; APIGENIN; BETA CATENIN; CURCUMIN; FISETIN; FLAVONOID; GENISTEIN; PLANT MEDICINAL PRODUCT; QUERCETIN; RESVERATROL; WNT PROTEIN; ANTINEOPLASTIC AGENT; CYTOKINE; SONIC HEDGEHOG PROTEIN;

CANCER RECURRENCE; CANCER THERAPY; EPITHELIAL MESENCHYMAL TRANSITION; HEDGEHOG; HUMAN; METASTASIS; METASTASIS INHIBITION; NONHUMAN; REVIEW; TEA; TUMOR INVASION; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; ANIMAL; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CYTOKINES; EPITHELIAL-MESENCHYMAL TRANSITION; HEDGEHOG PROTEINS; HUMANS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; WNT PROTEINS;

EID: 84989278712     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12299     Document Type: Review

References (121)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
2. Feitelson MA, Arzumanyan A, Kulathinal RJ, et al. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol 2015;35:S25–S54.
3. Heerboth S, Housman G, Leary M, et al. EMT and tumor metastasis. Clin Transl Med. 2015;4:1.
4. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–1437.
5. Obenauf AC, Massagué J. Surviving at a distance: organ-specific metastasis. Trends cancer. 2015;1:76–91.
6. Sun Y, Ma L. The emerging molecular machinery and therapeutic targets of metastasis. Trends Pharmacol Sci. 2015;36:349–359.
7. Leblanc R, Peyruchaud O. Metastasis: new functional implications of platelets and megakaryocytes. Blood. 2016;128:24–31.
8. García-Román J, Zentella-Dehesa A. Vascular permeability changes involved in tumor metastasis. Cancer Lett. 2013;335:259–269.
9. Vaupel P. Metabolic microenvironment of tumor cells: a key factor in malignant progression. Exp Oncol. 2010;32:125–127.
10. Pein M, Oskarsson T. Microenvironment in metastasis: roadblocks and supportive niches. Am J Physiol Cell Physiol. 2015;309:C627–C638.
11. Aceto N, Toner M, Maheswaran S, Haber DA. En route to metastasis: circulating tumor cell clusters and epithelial-to-mesenchymal transition. Trends Cancer. 2015;1:44–52.
12. Oh J, Hlatky L, Jeong YS, Kim D. Therapeutic Effectiveness of Anticancer Phytochemicals on Cancer Stem Cells. Toxins (Basel). 2016;8:199.
13. de Boer A, Urlings MJ, Bast A. Active ingredients leading in health claims on functional foods. J Funct Foods. 2016;20:587–593.
14. Maru GB, Hudlikar RR, Kumar G, Gandhi K, Mahimkar MB. Understanding the molecular mechanisms of cancer prevention by dietary phytochemicals: from experimental models to clinical trials. World J Biol Chem. 2016;7:88.
15. Mock CD, Jordan BC, Selvam C. Recent advances of curcumin and its analogues in breast cancer prevention and treatment. RSC Advances. 2015;5:75575–75588.
16. Kwon Y. Curcumin as a cancer chemotherapy sensitizing agent. J Korean Soc Appl Biol Chem. 2014;57:273–280.
17. Li Y, Niu Y, Sun Y, et al. An Apple Oligogalactan Potentiates the growth inhibitory effect of celecoxib on colorectal cancer. Nutr Cancer. 2014;66:29–37.
18. Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules. 2011;16:4567–4598.
19. Moiseeva EP, Almeida GM, Jones GD, Manson MM. Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther. 2007;6:3071–3079.
20. Weiss JF, Landauer MR. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology. 2003;189:1–20.
21. Reagan-Shaw S, Eggert D, Mukhtar H, Ahmad N. Antiproliferative effects of apple peel extract against cancer cells. Nutr Cancer. 2010;62:517–524.
22. Diepenbruck M, Christofori G. Epithelial–mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr Opin Cell Biol. 2016;43:7–13.
23. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Investig. 2003;112:1776–1784.
24. Du Toit A. Cell signalling: when signals cross. Nat Rev Mol Cell Biol. 2015;16:204.
25. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–142.
26. Tang Y, Herr G, Johnson W, Resnik E, Aho J. Induction and analysis of epithelial to mesenchymal transition. J Vis Exp. 2013;27:e50478.
27. Derksen PW, Liu X, Saridin F, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 2006;10:437–449.
28. Sánchez-Tilló E, Liu Y, de Barrios O, et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci. 2012;69:3429–3456.
29. Naber HP, Drabsch Y, Snaar-Jagalska BE, ten Dijke P, van Laar T. Snail and Slug, key regulators of TGF-β-induced EMT, are sufficient for the induction of single-cell invasion. Biochem Biophys Res Commun. 2013;435:58–63.
30. McGrail DJ, Mezencev R, Kieu QM, McDonald JF, Dawson MR. SNAIL-induced epithelial-to-mesenchymal transition produces concerted biophysical changes from altered cytoskeletal gene expression. FASEB J. 2015;29:1280–1289.
31. Unternaehrer JJ, Zhao R, Kim K, et al. The epithelial-mesenchymal transition factor SNAIL paradoxically enhances reprogramming. Stem Cell Rep. 2014;3:691–698.
32. Arias JI, Aller MA, Arias J. Cancer cell: using inflammation to invade the host. Mol Cancer. 2007;6:1.
33. Zhang J, Liu J. Tumor stroma as targets for cancer therapy. Pharmacol Ther. 2013;137:200–215.
34. Renaud S, Guenot D, Falcoz PE, Massard G, Beau-Faller M. Role of hypoxia in epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC). Eur Respir J. 2014;44(Suppl 58):P814.
35. Yang MH, Wu KJ. TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle. 2008;7:2090–2096.
36. Chaffer CL, Thompson EW, Williams ED. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs. 2007;185:7–19.
37. Daugherty RL, Gottardi CJ. Phospho-regulation of β-catenin adhesion and signaling functions. Physiology. 2007;22:303–309.
38. Kashiwagi S, Yashiro M, Takashima T, et al. Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer. 2010;103:249–255.
39. Nakopoulou L, Mylona E, Papadaki I, et al. Study of phospho-β-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Mod Pathol. 2006;19:556–563.
40. Li Z, Jiao X, Wang C, et al. Cyclin D1 induction of cellular migration requires p27KIP1. Cancer Res. 2006;66:9986–9994.
41. Srinivasan A, Thangavel C, Liu Y, et al. Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer. Mol Carcinog. 2016;55:743–756.
42. Dorai T, Diouri J, O'Shea O, Doty SB. Curcumin inhibits prostate cancer bone metastasis by up-regulating bone morphogenic protein-7 in vivo. J Cancer Ther. 2014;5:369.
43. Shan S, Lv Q, Zhao Y, et al. Wnt/β-catenin pathway is required for epithelial to mesenchymal transition in CXCL12 over expressed breast cancer cells. Int J Clin Exp Pathol. 2015;8:12357.
44. MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9–26.
45. Duan P, Bonewald LF. The role of the wnt/β-catenin signaling pathway in formation and maintenance of bone and teeth. Int J Biochem Cell Biol. 2016;77:23–29.
46. Strzyz P. Cancer biology: TGF [beta] and EMT as double agents. Nat Rev Mol Cell Biol. 2016;17:202–203.
47. Macias MJ, Martin-Malpartida P, Massagué J. Structural determinants of Smad function in TGF-β signaling. Trends Biochem Sci. 2015;40:296–308.
48. Hasan M, Neumann B, Haupeltshofer S, et al. Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation. Immunol Cell Biol. 2015;93:662–672.
49. Panahi Y, Darvishi B, Ghanei M, Jowzi N, Beiraghdar F, Varnamkhasti BS. Molecular mechanisms of curcumins suppressing effects on tumorigenesis, angiogenesis and metastasis, focusing on NF-κB pathway. Cytokine Growth Factor Rev. 2016;28:21–29.
50. Zhang K, Zhaos J, Liu X, et al. Activation of NF-B upregulates Snail and consequent repression of E-cadherin in cholangiocarcinoma cell invasion. Hepatogastroenterology. 2010;58:1–7.
51. Ingvarsson S, Chen H, Kristjánsdóttir S, Jónasson JG, Magnússon JB, Egilsson V. Alterations of E-cadherin and β-catenin in gastric cancer. BMC Cancer. 2001;1:16.
52. Scheel C, Eaton EN, Li SH, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011;145:926–940.
53. Scheel C, Eaton EN, Li SH, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011;145:926–940.
54. Kazi MM, Trivedi TI, Kobawala TP, Ghosh NR. The Potential of Wnt Signaling Pathway in Cancer: A Focus on Breast Cancer. Cancer Transl Med. 2016;2:55.
55. Spranger S, Gajewski TF. A new paradigm for tumor immune escape: β-catenin-driven immune exclusion. J Immunother Cancer. 2015;3:1.
56. Marcucci F, Stassi G, De Maria R. Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discovery. 2016;15:311–325.
57. Takebe N, Miele L, Harris PJ, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12:445–464.
58. Gonnissen A, Isebaert S, Haustermans K. Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened. Oncotarget. 2015;6:13899–13913.
59. di Magliano MP, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 2003;3:903–911.
60. Pan Y, Bai CB, Joyner AL, Wang B. Sonic hedgehog signaling regulates Gli2 transcriptional activity by suppressing its processing and degradation. Mol Cell Biol. 2006;26:3365–3377.
61. Yao E, Chuang PT. Hedgehog signaling: from basic research to clinical applications. J Formos Med Assoc. 2015;114:569–576.
62. Justilien V, Fields AP. Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells. Clin Cancer Res. 2015;21:505–513.
63. Takebe N, Miele L, Harris PJ, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12:445–464.
64. Merchant AA, Matsui W. Targeting Hedgehog—a cancer stem cell pathway. Clin Cancer Res. 2010;16:3130–3140.
65. Ma J, Cheng J, Gong Y, Tian L, Huang Q. Downregulation of Wnt signaling by sonic hedgehog activation promotes repopulation of human tumor cell lines. Dis Model Mech. 2015;8:385–391.
66. Sokol SY. Spatial and temporal aspects of Wnt signaling and planar cell polarity during vertebrate embryonic development. Semin Cell Dev Biol. 2015;42:78–85.
67. Price MA, Kalderon D. Proteolysis of the Hedgehog signaling effector Cubitus interruptus requires phosphorylation by Glycogen Synthase Kinase 3 and Casein Kinase 1. Cell. 2002;108:823–835.
68. Day TF, Yang Y. Wnt and hedgehog signaling pathways in bone development. J Bone Joint Surg. 2008;90(Supplement 1):19–24.
69. Cohen MM. The hedgehog signaling network. Am J Med Genet A. 2003;123:5–28.
70. Yang SH, Andl T, Grachtchouk V, et al. Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/β-catenin signaling. Nat Genet. 2008;40:1130–1135.
71. Amado NG, Fonseca BF, Cerqueira DM, Neto VM, Abreu JG. Flavonoids: potential Wnt/beta-catenin signaling modulators in cancer. Life Sci. 2011;89:545–554.
72. Vezza T, Rodríguez-Nogales A, Algieri F, Utrilla MP, Rodriguez-Cabezas ME, Galvez J. Flavonoids in inflammatory bowel disease: a review. Nutrients. 2016;8:211.
73. Romagnolo DF, Selmin OI. Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr. 2012;31:206–238.
74. Liu X, Li L, Lv L, et al. Apigenin inhibits the proliferation and invasion of osteosarcoma cells by suppressing the Wnt/β-catenin signaling pathway. Oncol Rep 2015;34:1035–1041.
75. Lall RK, Adhami VM, Mukhtar H. Dietary flavonoid fisetin for cancerprevention and treatment. Mol Nutr Food Res. 2016;60:1396–1405.
76. Lai C-S, Pan M-H. Mechanism for possible chemopreventive effects of natural dietary compounds on smoking-induced tumorigenesis. J Exp Clin Med. 2011;3:262–271.
77. Oh S, Gwak J, Park S, et al. Green tea polyphenol EGCG suppresses Wnt/β-catenin signaling by promoting GSK-3β-and PP2A-independent β-catenin phosphorylation/degradation. BioFactors. 2014;40:586–595.
78. Gao Z, Xu Z, Hung MS, et al. Promoter demethylation of WIF-1 by epigallocatechin-3-gallate in lung cancer cells. Anticancer Res. 2009;29:2025–2030.
79. Dashwood WM, Orner GA, Dashwood RH. Inhibition of β-catenin/Tcf activity by white tea, green tea, and epigallocatechin-3-gallate (EGCG): minor contribution of H 2 O 2 at physiologically relevant EGCG concentrations. Biochem Biophys Res Commun. 2002;296:584–588.
80. Gao Z, Xu Z, Hung MS, et al. Promoter demethylation of WIF-1 by epigallocatechin-3-gallate in lung cancer cells. Anticancer Res. 2009;29:2025–2030.
81. Pahlke G, Ngiewih Y, Kern M, et al. Impact of quercetin and EGCG on key elements of the Wnt pathway in human colon carcinoma cells. J Agric Food Chem. 2006;54:7075–7082.
82. Mount JG, Muzylak M, Allen S, et al. Evidence that the canonical Wnt signalling pathway regulates deer antler regeneration. Dev Dyn. 2006;235:1390–1399.
83. Bose M, Hao X, Ju J, et al. Inhibition of tumorigenesis in Apc Min/+ mice by a combination of (–)-epigallocatechin-3-gallate and fish oil. J Agric Food Chem. 2007;55:7695–7700.
84. Liu L, Lai CQ, Nie L, et al. The modulation of endothelial cell gene expression by green tea polyphenol-EGCG. Mol Nutr Food Res. 2008;52:1182–1192.
85. Kim J, Zhang X, Rieger-Christ KM, et al. Suppression of Wnt signaling by the green tea compound (–)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells requirement of the transcriptional repressor HBP1. J Biol Chem. 2006;281:10865–10875.
86. Tang GQ, Yan TQ, Guo W, et al. (−)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells. J Cancer Res Clin Oncol. 2010;136:1179–1185.
87. Inbaraj BS, Chen BH. Isoflavones in foods and ingestion in the diet. In: Victor R. Preedy, ed. Isoflavones: Chemistry, Analysis, Function and Effects. RCS publication, UK 2012:28.
88. Bhagwat S, Haytowitz DB, Holden JM. USDA database for the flavonoid content of selected foods, Release 3.1. Beltsville: US Department of Agriculture; 2011.
89. Spagnuolo C, Russo GL, Orhan IE, et al. Genistein and cancer: current status, challenges, and future directions. Adv Nutr. 2015;6:408–419.
90. Park CH, Hahm ER, Lee JH, et al. Inhibition of β-catenin-mediated transactivation by flavanone in AGS gastric cancer cells. Biochem Biophys Res Commun. 2005;331:1222–1228.
91. Li Y, Wang Z, Kong D, et al. Regulation of Akt/FOXO3a/GSK-3β/AR signaling network by isoflavone in prostate cancer cells. J Biol Chem. 2008;283:27707–27716.
92. Sarkar FH, Li Y, Wang Z, et al. Cellular signaling perturbation by natural products. Cell Signal. 2009;21:1541–1547.
93. Su Y, Simmen RC. Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates β-catenin signaling in mammary epithelial cells. Carcinogenesis. 2009;30:331–339.
94. Su Y, Simmen FA, Xiao R, et al. Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors. Physiol Genomics. 2007;30:8–16.
95. Qadri SM, Föller M, Lang F. Inhibition of suicidal erythrocyte death by resveratrol. Life Sci. 2009;85:33–38.
96. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discovery. 2006;5:493–506.
97. Bisht K, Wagner K-H, Bulmer AC. Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto-and DNA-protective dietary compounds. Toxicology. 2010;278:88–100.
98. Michels G, et al. Resveratrol induces apoptotic cell death in rat H4IIE hepatoma cells but necrosis in C6 glioma cells. Toxicology. 2006;225:173–182.
99. Busquets S, Ametller E, Fuster G, et al. Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett. 2007;245:144–148.
100. Olas B, Wachowicz B, Tomczak A, et al. Comparative anti-platelet and antioxidant properties of polyphenol-rich extracts from: berries of Aronia melanocarpa, seeds of grape and bark of Yucca schidigera in vitro. Platelets. 2008;19:70–77.
101. Knobloch J, Hag H, Jungck D, et al. Resveratrol impairs the release of steroid-resistant cytokines from bacterial endotoxin-exposed alveolar macrophages in chronic obstructive pulmonary disease. Basic Clin Pharmacol Toxicol. 2011;109:138–143.
102. Lee SY, Lee HJ, Sikder MA, et al. Resveratrol inhibits mucin gene expression, production and secretion from airway epithelial cells. Phytother Res. 2012;26:1082–1087.
103. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–890.
104. Hope C, Planutis K, Planutiene M, et al. Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer prevention. Mol Nutr Food Res. 2008;52(Suppl. 1):S52–S61.
105. Slusarz A, Shenouda NS, Sakla MS, et al. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 2010;70:3382–3390.
106. Shan B-E, Wang M-X, Li R-Q. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/β-catenin signaling pathway. Cancer Invest. 2009;27:604–612.
107. Li W, Zhao Y, Tao B, et al. Effects of quercetin on hedgehog signaling in chronic myeloid leukemia KBM7 cells. Chin J Integr Med. 2014;20:776–781.
108. Srivastava RK, Tang SN, Zhu W, et al. Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells. Front Biosci (Elite Ed). 2011;3:515.
109. Anand P, Sundaram C, Jhurani S, et al. Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett. 2008;267:133–164.
110. Xu J, Fu Y, Chen A. Activation of peroxisome proliferator-activated receptor-γ contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol. 2003;285:G20–G30.
111. Lian N, Jiang Y, Zhang F, et al. Curcumin regulates cell fate and metabolism by inhibiting hedgehog signaling in hepatic stellate cells. Lab Invest. 2015;95:790–803.
112. Leow PC, Tian Q, Ong ZY, et al. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells. Invest New Drugs. 2010;28:766–782.
113. Shin HW, Park SY, Lee KB, et al. Down-regulation of Wnt signaling during apoptosis of human hepatic stellate cells. Hepatogastroenterology. 2008;56:208–212.
114. Elamin MH, Shinwari Z, Hendrayani SF, et al. Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Mol Carcinog. 2010;49:302–314.
115. Banerjee M, Tripathi LM, Srivastava VM, et al. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunotoxicol. 2003;25:213–224.
116. Wertz K. Lycopene effects contributing to prostate health. Nutr Cancer. 2009;61:775–783.
117. Kovalenko PL, Zhang Z, Cui M, et al. 1, 25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genom. 2010;11:1.
118. Kaler P, Augenlicht L, Klampfer L. Macrophage-derived IL-1β stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene. 2009;28:3892–3902.
119. Bijlsma MF, Peppelenbosch MP, Arnold Spek C. (Pro-) vitamin D as treatment option for hedgehog-related malignancies. Med Hypotheses. 2008;70:202–203.
120. Tang JY, So P-L, Epstein EH. Novel Hedgehog pathway targets against basal cell carcinoma. Toxicol Appl Pharmacol. 2007;224:257–264.
121. Xie J, Yang Z, Zhou C, et al. Nanotechnology for the delivery of phytochemicals in cancer therapy. Biotechnol Adv. 2016;34:343–353.